



## **Enanta Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference**

January 4, 2022

[Download this Press Release](#)

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 40<sup>th</sup> Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 3:00 p.m. ET.

A live webcast of the presentation will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at [www.enanta.com](http://www.enanta.com). A replay of the webcast will be available following the presentation and will be archived for at least 30 days.

### **About Enanta**

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta's research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and SARS-CoV-2 (COVID-19). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta's research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit [www.enanta.com](http://www.enanta.com) for more information.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220104005184/en/): <https://www.businesswire.com/news/home/20220104005184/en/>

### **Media and Investor Contact**

Jennifer Viera  
617-744-3848  
[jviera@enanta.com](mailto:jviera@enanta.com)

Source: Enanta Pharmaceuticals, Inc.